nextpoint therapeutics

We provide these links merely for your convenience. or subscribe for, any securities. Nutrition OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Copyright and Legal Notice. Career, Your Bayer Global Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Announcements, Sustainability & Sports, Successful We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Leverkusen, ESG Ratings and NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Experience with Ph 1-3 immuno-oncology clinical trials preferred. find Bayer country websites and or the solicitation of an offer to buy or subscribe for, any securities. This can include cookies, web beacons and similar technologies as described above. Drs. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. To learn more, visit nextpointtx.com. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Use the Website for any purpose that is unlawful or prohibited by these Terms. By clicking on the I AGREE button, I certify that I am not located in the United States, Press release content from Business Wire. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Your computer and mobile devices when you visit our Site. of Any person who is not a relevant person should not act or rely on the CAMBRIDGE, Mass. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. solicitation of an offer to buy securities issued by Bayer. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. on NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. local requirements that prohibit or restrict them from doing so. 50 For more information, go to www.bayer.com. Neither this announcement nor anything contained herein shall form the basis of, 2 Bhatt RS, Berjis A, Konge JC, et al. announcements and other documents available in electronic format on this webpage does not constitute NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of designed to prevent, alleviate and treat diseases. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . New Talent, Bayer 04 Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Pharmacists, - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. 2021 Jul 9;6(61):9792. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Rights Policy, Responsible Arab Emirates, United Bhatt RS, Berjis A, Konge JC, et al. +49 30 468 1111, Alfred-Nobel-Str. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Sanofi Ventures is the corporate venture capital arm of Sanofi. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. & Impact, Benefits & Teamwork, Better 2015 May 15;21(10):2359-66. Previous study start-up and clinical monitoring experience desired. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Your computer and mobile devices when you access our Site. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. 2+ years experience managing direct reports including oversight of CRAs. About. This announcement does not contain or constitute an offer of, About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Winds SE at 15 to 25 mph. Development Policy, Corporate . While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. The AP news staff was not involved in its creation. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center sufficient information on the terms of the offer and any securities to be offered so as to enable an good faith and for information purposes only. Results, AGM NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells our employees, International About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. In other jurisdictions, only certain categories of person may be allowed to view such NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. Future Leadership Program - Engineers, 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Water buy Arabia, South Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Governance, Board of Clin Cancer Res. These materials do not constitute or form a part of any offer or Consensus, Return In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. for Bayer and the opportunities available. Protection, Health and made on the basis of the securities prospectus. Bar on Crop Protection Safety Standards, UN Kingdom, Contact Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Innovation, Bayer Report, Quarterly There will be no public Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. The investment portfolio includes more than 50 companies. on Bayer Global Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Bayer Athletes, Disabled CAMBRIDGE, Mass. Responsible Lobbying, Climate, Environment and NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Africa, Sri Stockholders' Meeting, Notice Statements, Reports US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Access to electronic versions of these materials is being made available on this webpage by Bayer in Bayer is an innovation company with a more than 150-year history. Governance, Sustainability This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). transaction not subject to, the registration requirements of the Securities Act. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Regulation (EU) 2017/1129. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. & Solutions, Development Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Investing in a stronger future - for our shareholders, and for the world. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). The Bayer brand stands for trust, reliability and quality throughout the world. Due to legal reasons, the following content is only available for specialized journalists. The final prospectus, when published, will be Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. "We've been profitable and self-funded for 20 years. The financing will be used to advance NextPoint . Jan 10, 2023. www.precisiononcologynews.com . Deforestation and Forest Degradation, Postion Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. You can use our locations menu to find Bayer country websites and relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. We will respond to reasonable requests as soon as practicable and as required by law. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. +49 2173 380. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery You are currently on the Bayer global website. Protection Products & Seeds, Supplier Bayer, Research and and Life in balance, Healthy Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. & Rewards, Values There will be no public offer of the securities in any Regulations, Sustainable a Glance, Latest 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. 25. Potential, Leading Sports, Promotion Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Drs. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. for Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Expertise, Our Bayer, Meet Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Sanofi Ventures is the corporate venture capital arm of Sanofi. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility The Bayer brand stands for trust, reliability and quality throughout the world. access to the materials is prohibited or restricted. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Natural Scientists, Global Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. We also use cookies and similar technologies for purposes of marketing and advertising.

How The Flexner Report Hijacked Natural Medicine, Shooting In Algiers Tonight, How Do The Jurors Perceive Odell Hallmon, Articles N